Ireland
--:--IST
Priya Life Science Regulatory
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 10 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
977Linked to a medicine page here

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
  • Recommended: the NHS in England should fund it for the use it is licensed for.
  • Optimised: recommended, but for a narrower group of patients than the licence covers.
  • Cancer Drugs Fund / Innovative Medicines Fund: funded for a limited period while more evidence is collected.
  • Only in research: to be used only as part of a study.
  • Not recommended: NICE decided the NHS should not fund it for this use.
  • Terminated: the company did not send evidence, so NICE could not make a recommendation.

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Appraisals matching “Bevacizumab”

21 appraisals, newest first
AppraisalMedicine pageNICE recommendationPublishedStatus
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
NICE TA1136
BevacizumabOptimised25 Feb 2026Current
Bevacizumab gamma for treating wet age-related macular degeneration
NICE TA1022
—Recommended4 Dec 2024Current
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
NICE TA1008
—Recommended25 Sep 2024Current
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
NICE TA946
OlaparibRecommended17 Jan 2024Current
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA939
PembrolizumabOptimised13 Dec 2023Current
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA885
PembrolizumabRecommended (Cancer Drugs Fund)3 May 2023Replaced by TA939
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
NICE TA693
OlaparibOptimised (Cancer Drugs Fund)28 Apr 2021Replaced by TA946
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
NICE TA666
AtezolizumabOptimised16 Dec 2020Current
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
NICE TA560
BevacizumabTerminated (no company submission)20 Feb 2019Current
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
NICE TA436
BevacizumabTerminated (no company submission)22 Mar 2017Current
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
NICE TA353
BevacizumabTerminated (no company submission)26 Aug 2015Current
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
NICE TA285
BevacizumabNot recommended22 May 2013Current
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
NICE TA284
BevacizumabNot recommended22 May 2013Current
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
NICE TA263
BevacizumabNot recommended22 Aug 2012Current
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
NICE TA242
Cetuximab, Bevacizumab, PanitumumabNot recommended25 Jan 2012Current
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
NICE TA214
BevacizumabNot recommended23 Feb 2011Current
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
NICE TA212
BevacizumabNot recommended15 Dec 2010Current
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
NICE TA178
Bevacizumab, Sorafenib, Temsirolimus, SunitinibNot recommended26 Aug 2009Current
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
NICE TA148
BevacizumabTerminated (no company submission)25 Jun 2008Current
Bevacizumab for the first-line treatment of metastatic breast cancer
NICE TA147
BevacizumabTerminated (no company submission)25 Jun 2008Current
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
NICE TA118
Bevacizumab, CetuximabNot recommended24 Jan 2007
Updated 1 Jan 2012
Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 10 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.